What is the role of arsenic in newly diagnosed APL?

Rodeghiero, 1994, The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia, Leukemia, 8, S20 Asou, 2007, A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study, Blood, 110, 59, 10.1182/blood-2006-08-043992 Avvisati, 2003, AIDA: the Italian way of treating acute promyelocytic leukemia (APL), final act, Blood, 102, 142a Ades, 2008, Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results, Blood, 111, 1078, 10.1182/blood-2007-07-099978 Soignet, 2001, United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia, Journal of Clinical Oncology, 19, 3852, 10.1200/JCO.2001.19.18.3852 Glienke, 2006, Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds, Leukemia & Lymphoma, 47, 1629, 10.1080/10428190600625398 Mathieu, 2006, Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells, Annals of the New York Academy of Sciences, 1090, 203, 10.1196/annals.1378.022 Ninomiya, 2006, Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy, Haematologica, 91, 1571 Powell, 2007, Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710, Journal of Clinical Oncology, 25, 1s, 10.1200/jco.2007.25.18_suppl.2 Liu, 2006, Long-term follow-up confirms the benefit of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) as front line therapy for newly diagnosed acute promyelocytic leukemia (APL), Blood, 108, 170a, 10.1182/blood.V108.11.565.565 Mathews, 2006, Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity, Blood, 107, 2627, 10.1182/blood-2005-08-3532 Ades, 2006, Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group, Journal of Clinical Oncology, 24, 5703, 10.1200/JCO.2006.08.1596 Sanz, 2004, Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group, Blood, 103, 1237, 10.1182/blood-2003-07-2462 Shen, 2004, All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia, Proceedings of the National Academy of Sciences of the United States of America, 101, 5328, 10.1073/pnas.0400053101 Estey, 2006, Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia, Blood, 107, 3469, 10.1182/blood-2005-10-4006 Zhang, 1999, The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia, Journal of Biological Regulators and Homeostatic Agents, 13, 195 Ghavamzadeh, 2006, Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy, Annals of Oncology, 17, 131, 10.1093/annonc/mdj019 Ghaffari, 2007, Telomerase activity and telomere length in APL: may be proliferative and prognosti markers, Blood, 110, 126b, 10.1182/blood.V110.11.4236.4236 Mathews, 2007, Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen, Haematologica, 92, 994, 10.3324/haematol.10802 Alimoghaddam, 2007, Risk factors for early mortality, relapse and overall survival in new cases of APL treated by arsenic trioxide, Journal of Clinical Oncology, 25, 374s, 10.1200/jco.2007.25.18_suppl.7069 Stock, 2008, High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): correlation with diagnostic features and treatment outcome (CALGB 9710), Journal of Clinical Oncology, 26, 372s, 10.1200/jco.2008.26.15_suppl.7002 Gale, 2005, Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia, Blood, 106, 3768, 10.1182/blood-2005-04-1746 Sainty, 2000, Blood, 96, 1287 Ito, 2004, Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia, Leukemia & Lymphoma, 45, 1783, 10.1080/10428190410001683624 Douer, 2003, Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARalpha fusion gene, British Journal of Haematology, 122, 563, 10.1046/j.1365-2141.2003.04480.x Wang, 1993, Problems existing in differentiation therapy of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA), Blood Cells, 19, 633 Tobita, 1997, Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid, Blood, 90, 967, 10.1182/blood.V90.3.967 Kini, 2001, Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid, Blood, 97, 3919, 10.1182/blood.V97.12.3919 Banavali, 2005, A novel, efficacious therapeutic approach to patients with acute promyelocytic leukemia (APL) using differentiating agent and metronomic chemotherapy (CT), Blood, 106, 264a, 10.1182/blood.V106.11.900.900 Kini, 2005, Vascular endothelial growth factor (VEGF) is a critical autocrine survival factor in acute promyelocytic leukemia (APL), Blood, 106, 772a, 10.1182/blood.V106.11.2751.2751 Sassano, 2007, Suppressive effects of statins on acute promyelocytic leukemia cells, Cancer Research, 67, 4524, 10.1158/0008-5472.CAN-06-3686